30几岁慢淋转化求助！！帮帮我们吧！

Ivy-

7月颈部腹股沟淋巴结肿大在本地医院穿刺，结果是慢淋转化，随后到广州中肿做病理会诊，结果一样
现在在本地医院化疗r-chop+泽布替尼，今天二疗结束，大神们求问还有必要寄到北京专家再做一次病理吗？后续怎么治疗啊？？医生也说很罕见，怎么办啊他还这么年轻求求大神们帮帮忙吧！！@洪飞 @橙色雨丝 @晴天-淋巴瘤之家

来自苹果APP客户端

Ivy-

这是二疗前的ct结果

来自苹果APP客户端

锦鲤护体

看二疗应该是向好的方向发展 加油

来自苹果APP客户端

橙色雨丝

不需要会诊，缓解后异体移植。

Ivy-

橙色雨丝 发表于 2025-08-22 10:39
不需要会诊，缓解后异体移植。

谢谢大神回复！只能异体了吗？异体很担心排异

来自苹果APP客户端

橙色雨丝

Ivy- 发表于 2025-8-22 11:10
谢谢大神回复！只能异体了吗？异体很担心排异

Prognosis
In the last decade, survival of patients with CLL has improved with the development of BTKis and B-cell lymphoma 2 inhibitors (BCL2is) but this progress has not translated to improved survival for RT. In large pooled cohorts, meta-analyses, and population-based studies, the median OS for patients with RT ranges from 8.7 to 12 months.3,4,56,57 Recent retrospective studies, evaluating RT cohorts in which some patients were treated with BTKis or BCL2is, reported median OS ranges from 3.3 to 19.9 months.10,26,58,59 These data highlight that patients with RT continue to have dismal outcomes in the era of targeted therapy. Hence, there is currently no effective treatment for RT. Chemoimmunotherapy regimens (ie, R-CHOP [rituximab, cyclophosphamide, doxorubicin, Oncovin (vincristine), and prednisone]) remain the de facto standard of care despite poor outcomes with its use. 年轻患者的治疗应该激进一点。

晚风也温柔

别慌  先cr再说  还有CART呢

来自安卓APP客户端

Ivy-

橙色雨丝 发表于 2025-08-22 11:28
Prognosis
In the last decade, survival of patients with CLL has improved with the development of BTKis and B-cell lymphoma 2 inhibitors (BCL2is) but this progress has not translated to improved survival for RT. In large pooled cohorts, meta-analyses, and population-based studies, the median OS for patients with RT ranges from 8.7 to 12 months.3,4,56,57 Recent retrospective studies, evaluating RT cohorts in which some patients were treated with BTKis or BCL2is, reported median OS ranges from 3.3 to 19.9 months.10,26,58,59 These data highlight that patients with RT continue to have dismal outcomes in the era of targeted therapy. Hence, there is currently no effective treatment for RT. Chemoimmunotherapy regimens (ie, R-CHOP [rituximab, cyclophosphamide, doxorubicin, Oncovin (vincristine), and prednisone]) remain the de facto standard of care despite poor outcomes with its use. 年轻患者的治疗应该激进一点。

那cart不建议吗？

来自苹果APP客户端

橙色雨丝

Ivy- 发表于 2025-08-22 14:23
那cart不建议吗？

CAR-T对慢淋的缓解率只有弥漫大B的一半左右。

来自安卓APP客户端

常春藤2027

这么年轻，异体移植获益大

来自安卓APP客户端